Assembling intelligence…
IGF::OT::IGF PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS
| Company | Orders | Obligated | Latest order end |
|---|---|---|---|
| THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 9 | $5.5M | 2023-06-16 |
| HHSN26100004 THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · National Institutes of Health | $979K | 2021-06-30 |
| 75N91018F00009 THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · National Institutes of Health | $849K | 2022-12-16 |
| 75N91018F00008 THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · National Institutes of Health | $778K | 2023-06-16 |
| 75N91018F00007 THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · National Institutes of Health | $729K | 2021-04-19 |
| HHSN26100006 THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · National Institutes of Health | $714K |
| 2020-12-31 |